Leerink analyst Geoffrey Porges believes Alexion's Soliris is still likely to be approved for the treatment of refractory myasthenia gravis despite the "unusual circumstance" of failing to achieve the primary efficacy endpoint. Given Soliris' positive safety profile, "strong" anecdotal support for the drug's benefit in myasthenia gravis, and positive practitioner sentiment, the analyst says he remains positive about the eventual approval, although he acknowledges timelines may be extended. Porges reiterates an Outperform rating and $200 price target on the shares.